GRAIL Strategy and Business Model

Executive Overview

GRAIL is a cancer-screening company focused on multi-cancer early detection from a single blood draw. Its core product, Galleri, is a laboratory-developed blood test marketed in the United States for adults with elevated cancer risk, such as those age 50 and older, and is positioned as a complement to existing guideline-recommended screening rather than a replacement for it. Founded in 2016 as an Illumina-backed venture and headquartered in Menlo Park, California, GRAIL operates at the intersection of genomics, molecular diagnostics, oncology, and laboratory services. The company returned to the public market in June 2024 after Illumina spun it off as an independent company. Strategically, GRAIL is trying to do something unusual: create a new screening category, build the clinical evidence and health-economic case behind that category, and scale a centralized testing model at the same time. Commercially, the business is centered on the U.S., while the United Kingdom has been important for large-scale evidence generation through the NHS-Galleri trial. FY2024 revenue was #N/A, but GRAIL remains in an investment-heavy stage, with substantial spending on clinical studies, R&D, medical affairs, and laboratory operations.

GRAIL at a Glance

Logo
Common name	GRAIL
Full legal name	GRAIL, Inc.
Headquarters	Menlo Park, California, USA
Ownership	Public company
Ticker	GRAL
Exchange	NASDAQ
Market Cap	$2.64B
Revenue (FY2024)	#N/A
Founding / major historical milestones	Founded in 2016 as an Illumina-backed early cancer detection company; Galleri launched commercially in the U.S. in 2021; reacquired by Illumina in 2021; spun off as an independent public company in 2024
Industry or industries	Multi-cancer early detection, liquid biopsy, molecular diagnostics, genomics
Key products or services	Galleri multi-cancer early detection blood test; centralized laboratory processing; physician ordering and patient access support
Geographic footprint	Commercial focus in the United States; major evidence-generation activity in the United Kingdom; operations centered in California and North Carolina
Business segments as officially reported	One operating and reportable segment
Company website	https://grail.com

1. What Is the Strategy of GRAIL?

GRAIL’s public materials consistently frame the company around earlier cancer detection, category creation, and evidence generation rather than broad diversification across diagnostics. Using the Playing to Win framework, the strategy can be summarized as follows.

1a. What is the winning aspiration of GRAIL?

GRAIL’s stated mission is to detect cancer early, when it can be cured. In practical strategic terms, that means making multi-cancer early detection clinically credible, operationally scalable, and eventually reimbursable enough to become a routine part of care for appropriate populations. Public disclosures emphasize improving outcomes by finding cancers that existing single-cancer screening programs often miss. GRAIL has not centered its public narrative on a near-term revenue or margin target; instead, the clearest aspiration is category leadership in multi-cancer early detection and broad adoption of blood-based screening alongside existing screening standards.
1b. Where does GRAIL play?

GRAIL is focused mainly on multi-cancer early detection screening for asymptomatic adults at elevated risk, particularly in the U.S. Its commercial focus is not all oncology diagnostics and not general lab testing. The company plays in provider-ordered screening, health-system adoption, employer-sponsored access, and longer-term payer reimbursement pathways. Geographically, the commercial business is concentrated in the United States, while the United Kingdom has been a strategically important proving ground through the NHS-Galleri trial. GRAIL is therefore choosing a narrow but potentially large market: blood-based screening for early cancer detection at population scale.
1c. How does GRAIL plan to win?

GRAIL appears to be trying to win through scientific differentiation and evidence depth rather than price. Galleri is designed to detect a shared cancer signal across more than 50 cancer types and to predict the cancer signal origin, which is a more ambitious value proposition than a single-cancer test. GRAIL also seeks advantage through large clinical datasets, real-world evidence, centralized laboratory quality, and workflow integration for physicians and health systems. Just as important, the company positions Galleri as an adjunct to existing screening, which lowers the burden of displacing entrenched screening modalities. A reasonable outside synthesis is that GRAIL must win on trust, data, and clinical utility before it can win on scale.
1d. What capabilities must GRAIL have in place?

To execute this strategy, GRAIL needs strong capabilities in methylation-based cancer biology, next-generation sequencing, machine-learning classification, assay development, and bioinformatics. It also needs large-scale clinical trial execution, medical affairs, market access and reimbursement work, health-economic analysis, and highly reliable centralized laboratory operations. Because the company is still early in commercialization, commercial capabilities matter as much as scientific ones: physician education, health-system implementation, enterprise selling, patient support, and revenue-cycle discipline all support adoption.
1e. What management systems does GRAIL require?

GRAIL needs management systems that keep science, evidence, quality, and commercialization tightly linked. That includes laboratory quality systems, regulatory and compliance oversight, clinical-study governance, commercial funnel tracking, reimbursement analytics, and cost-per-test monitoring. Since the 2024 spin-off, the company also needs standalone public-company systems in finance, IT, procurement, and governance. Because GRAIL is creating a new category while managing cash burn, management systems around capital allocation and milestone-based investment are especially important.

2. What Are the Current Strategic Initiatives of GRAIL?

Expand Galleri commercialization in the U.S. GRAIL’s public messaging has centered on broadening physician adoption, increasing use in health systems, and growing organized channels such as employers. In an early-category market, commercial expansion is partly a selling effort and partly a market-development effort.
Generate large-scale clinical and real-world evidence. GRAIL continues to emphasize studies such as the Circulating Cell-free Genome Atlas, PATHFINDER, and the NHS-Galleri trial in the United Kingdom. These studies are strategically important because they support physician confidence, payer dialogue, and the long-term clinical utility case.
Improve reimbursement and access. One of GRAIL’s most important initiatives is moving beyond a largely self-pay model. That requires health-economic evidence, coding and payment work, employer benefit design, and payer engagement.
Improve assay performance and unit economics. Public disclosures point to continued investment in laboratory process improvement, automation, software, and assay development. For GRAIL, lower cost per test and better throughput are not back-office goals; they are strategic enablers of broader adoption.
Operate successfully as a standalone public company after the 2024 spin-off. Separation from Illumina created a major execution agenda around standalone systems, governance, procurement, and operating infrastructure. For GRAIL, carve-out execution and category-building are happening in parallel.
Build the policy and clinical adoption foundation for multi-cancer early detection. Because the company is creating a relatively new category, medical affairs, publication strategy, and stakeholder education remain strategic initiatives rather than routine support functions.

3. What Is the Business Model of GRAIL?

GRAIL’s business model is primarily a per-test diagnostic services model. Customers are not buying a subscription platform or a piece of capital equipment; they are buying access to a blood-based multi-cancer early detection test, the associated laboratory processing, and a clinically interpretable result that includes cancer signal detection and cancer signal origin information when a signal is found.

Commercially, the model is still early. Galleri has been marketed in the U.S. at a public list price of $949, and the test is ordered through a physician. Today, a meaningful portion of demand appears to be self-pay or funded through employer and organized-access channels rather than broad, standard insurance reimbursement. That matters because adoption depends not just on clinical interest but also on willingness to pay and the ease of navigating the care pathway.

The revenue model is not subscription-based, but it has the potential to become repeat-driven if annual or periodic screening becomes standard practice for appropriate populations. Enterprise relationships with health systems, employers, or payers could also create recurring volume, even though each individual test is sold on a transactional basis.

Pricing power appears limited today. In the near term, clinical evidence, reimbursement progress, and physician adoption matter more than headline price increases. Gross margin is driven by sequencing reagents and consumables, laboratory utilization, logistics, failed-test rates, and the degree of automation. Operating margin and cash generation are heavily affected by R&D, clinical trials, medical affairs, and go-to-market spending. Because GRAIL currently has one major commercial product, business mix matters a great deal: higher-volume organized channels can improve lab utilization and customer acquisition efficiency, while a self-pay-heavy mix can support price but carry higher education and selling friction.

4. What Products and Services Does GRAIL Sell?

GRAIL is still a concentrated company from a product standpoint. Its business is centered on one core commercial offering.

Galleri. Galleri is GRAIL’s flagship and overwhelmingly most important commercial product. It is a multi-cancer early detection blood test intended to identify a cancer signal across many cancer types from a single blood draw and, when positive, predict the tissue of origin. Galleri is the company’s main revenue driver and the centerpiece of its strategy.
Laboratory testing and reporting services. What customers receive is not just a kit; it is a full testing workflow that includes sample logistics, centralized processing, sequencing, algorithmic analysis, and result reporting to the ordering clinician.
Access and support services around the test. GRAIL also provides the ordering and access infrastructure needed to use Galleri in practice, including physician-order pathways, patient support, and educational materials.

There is an important strategic distinction between current revenue products and platform development. Publicly, GRAIL’s future value may rest on broader assay and evidence development, but disclosed revenue today is closely tied to Galleri. That means GRAIL is not yet a diversified diagnostics portfolio company; it is a focused commercialization-stage company built around one major product and one core platform.

5. What Are the Key Competitors or Peers of GRAIL?

Direct competition is still somewhat unusual because the multi-cancer early detection category is early and no large incumbent has exactly the same commercial position as Galleri. In practice, GRAIL faces a mix of direct MCED developers, adjacent liquid-biopsy companies, and substitute screening pathways.

Guardant Health — A major liquid-biopsy company with cancer screening ambitions. Its current commercial focus includes blood-based colorectal cancer screening, but Guardant is also a relevant peer in early detection, assay development, and evidence generation.
Exact Sciences — Best known for Cologuard, Exact is a major cancer-screening company and an important strategic peer because it combines screening, evidence generation, and payer engagement at scale.
Freenome — A private company developing blood-based early cancer detection tests. Freenome is a closer development-stage peer than a scaled commercial competitor.
DELFI Diagnostics — A private liquid-biopsy company using fragmentomics and machine learning for early detection applications. It is relevant as a technology and category peer.
Natera — Not a direct MCED equivalent, but a strong adjacent peer in oncology blood testing, molecular diagnostics, and evidence-driven commercial expansion.
Roche / Foundation Medicine — More focused on precision oncology and companion diagnostics than screening, but still relevant as a large-scale oncology diagnostics benchmark.
Quest Diagnostics — Not a direct MCED developer, but an important business-model comparable in centralized testing, employer relationships, and payer access.
Labcorp — Another diagnostics infrastructure peer that matters less for direct MCED competition and more for scale, laboratory operations, and health-system relationships.

The most important substitutes are often not corporate peers at all, but established single-cancer screening modalities such as colonoscopy, mammography, Pap and human papillomavirus screening, low-dose computed tomography for lung cancer in eligible populations, and other guideline-based pathways. GRAIL’s challenge is to complement these standards without being treated as a discretionary add-on forever.

6. What Is the Marketing Strategy of GRAIL?

GRAIL’s marketing strategy appears to be evidence-led and medically mediated. Because Galleri is a physician-ordered test in a clinically sensitive category, scientific credibility matters more than mass-market brand advertising. Publications, conference presentations, medical affairs, and key-opinion-leader engagement are therefore central to demand creation.

The company also has to educate end users. That creates a hybrid marketing model: clinician-focused education on when and how to use Galleri, combined with patient-facing messaging that explains what the test does and does not do. One consistent theme in GRAIL’s messaging is that Galleri should complement existing recommended screening. That positioning is strategically important because it reduces perceived conflict with standard care.

Account-based marketing is likely especially relevant for health systems, employer groups, and organized access programs. For those customers, the message is broader than individual test performance; it includes implementation, follow-up workflow, employee benefits positioning, and health-economic value. Overall, marketing appears to be a necessary support capability, but not the main differentiator. Clinical evidence, medical trust, and reimbursement progress are more fundamental.

7. What Are the Key Customer Segments of GRAIL?

Adults at elevated cancer risk, especially age 50 and older. These are the primary end users of Galleri and the most visible demand pool in current commercialization.
Ordering clinicians. Primary care physicians, concierge physicians, preventive care providers, and certain specialists matter because Galleri is typically accessed through a clinician order.
Health systems and integrated delivery networks. These organizations can influence adoption at scale by embedding Galleri into preventive care pathways or population-health initiatives.
Employers and self-insured organizations. Employer-sponsored access is an important organized channel because it can reduce out-of-pocket friction and create repeatable testing programs.
Payers and reimbursement stakeholders. Today these are more strategic gatekeepers than mature revenue sources, but over time they could become decisive economic customers if coverage expands.

GRAIL is economically concentrated around one broad use case rather than around one named customer. Public disclosures do not suggest classic single-customer concentration. The bigger issue is that the company is still building category adoption across multiple buyer types at once.

8. What Is the Sales Model of GRAIL?

GRAIL uses a direct commercial model rather than a retail or distributor-heavy model. The company markets Galleri to physicians, health systems, and employer or organized-access channels, while the test itself is processed centrally by GRAIL. That structure gives the company control over quality, pricing, and customer experience, but it also makes commercial scale expensive because education and implementation are labor-intensive.

Physician-led ordering. Galleri typically reaches the end user through an ordering clinician, which means physician engagement is central to the go-to-market model.
Enterprise selling. Health systems, employers, and other organized channels are likely sold through dedicated account coverage rather than pure transactional selling.
Digital access support. GRAIL also uses online information and access pathways to help interested patients navigate ordering and blood draw logistics.
Centralized laboratory fulfillment. Samples flow to GRAIL’s laboratory network rather than being analyzed locally at point of care.

This channel structure affects growth in important ways. Direct selling improves customer intimacy and helps the company shape clinical use, but it also raises customer acquisition cost. Organized channels can improve growth efficiency and lab utilization, which is why channel prioritization is likely one of the most important strategic sales questions for GRAIL.

9. In What Geographies Does GRAIL Operate?

GRAIL’s commercial footprint is centered in the United States. That is where Galleri has been marketed commercially and where the company’s physician, patient, health-system, and employer access efforts are concentrated.

Operationally, GRAIL’s core footprint is anchored by its headquarters in Menlo Park, California and significant laboratory and operational activity in North Carolina. Those locations matter more than a broad global office map because the company uses a centralized testing model rather than a distributed local-lab model.

The United Kingdom is strategically important even though it is not the same thing as a broad commercial market for GRAIL. The NHS-Galleri trial has made the U.K. a major evidence-generation geography. Beyond that, GRAIL has not publicly presented itself as a widely commercialized global diagnostics company as of FY2024; it remains much more concentrated geographically than large diversified lab companies.

10. Who Are the Owners of GRAIL?

GRAIL is a public company listed on Nasdaq under the ticker GRAL. In June 2024, Illumina completed the spin-off of GRAIL, which shifted the company from parent-company ownership to a conventional public-company ownership structure. Based on public disclosures around the separation, GRAIL does not appear to have a single controlling shareholder; ownership is dispersed among public investors and changes over time through market trading.

11. How Is GRAIL Organized?

From a reporting standpoint, GRAIL is straightforward: it has one operating and reportable segment. That means investors do not get segment-level disclosure separating commercialization from platform development.

Practically, however, GRAIL appears to be organized functionally rather than by independent business unit. The major management domains likely include commercial, medical affairs and market access, clinical development and R&D, data science and bioinformatics, laboratory operations, regulatory and quality, and general corporate functions. Galleri is the single commercial franchise around which those functions are coordinated.

This matters because GRAIL is not a portfolio company with multiple semi-autonomous brands. It is a focused operating company where science, clinical evidence, lab execution, and commercialization have to move together. Since the 2024 spin-off, standalone corporate infrastructure has also become a more important part of the organization than it was under Illumina ownership.

12. How Does GRAIL Operate?

Day to day, GRAIL operates as a combination of a molecular diagnostics company, a centralized clinical laboratory, and a clinical-evidence organization.

Demand generation and ordering. A clinician, health system, employer-sponsored program, or consumer-initiated pathway leads to a physician order for Galleri.
Sample collection and logistics. Blood is drawn, packaged, and transported to GRAIL’s laboratory workflow.
Laboratory processing and sequencing. Samples are accessioned, prepared, sequenced, and run through bioinformatics analysis.
Algorithmic interpretation. GRAIL’s software and machine-learning models analyze methylation-derived signals to determine whether a cancer signal is present and, if so, where it likely originated.
Result reporting and support. Results are reported to the ordering clinician, who then manages patient communication and any downstream diagnostic workup.
Evidence generation and feedback loop. Clinical study operations, publications, and real-world data collection help refine the assay, support adoption, and strengthen the reimbursement case.

The biggest operational complexities are sample integrity, laboratory throughput, quality control, cost per test, and coordination of downstream diagnostic workflows when a positive result occurs. Unlike a mature routine lab test, Galleri also requires significant medical education and follow-up pathway design.

13. What Are the Growth Opportunities for GRAIL?

Broader reimbursement. The most important growth lever is likely improved coverage by employers, health systems, and eventually payers. If reimbursement broadens, the addressable market expands materially.
Greater physician and health-system adoption. Galleri remains early in penetration. Wider use by primary care and preventive-health channels could drive volume growth.
Repeat annual testing. Because multi-cancer screening can be repeat-driven, recurring volume could become much more important if the product becomes a routine annual test for defined populations.
Organized channel expansion. Employer-sponsored screening, integrated delivery networks, and population-health programs may offer more scalable growth than purely consumer-led adoption.
Assay improvements and cost reduction. Better sensitivity, workflow efficiency, and lower cost per test would improve both adoption and margins.
International opportunity. The U.K. evidence base may support future international expansion, although broad commercialization outside the U.S. remains a longer-term opportunity rather than a fully realized one.
Policy and guideline progress. Inclusion in clinical pathways or stronger reimbursement frameworks for multi-cancer early detection could materially accelerate the market.

The main constraints are equally clear: the need for stronger clinical utility and health-economic evidence, reimbursement friction, physician education requirements, evolving oversight of laboratory-developed tests, and the fact that GRAIL is still heavily dependent on one commercial product.

14. What Is the History of GRAIL?

2016: GRAIL was formed as an Illumina-backed company focused on using genomics and blood-based testing to detect cancer earlier.
2017 and after: The company raised large amounts of capital from prominent investors to pursue an ambitious clinical and technology development agenda.
2020: Illumina announced plans to reacquire GRAIL, highlighting how strategically important early cancer detection had become to the sequencing ecosystem.
2021: Illumina completed the GRAIL acquisition, and GRAIL launched Galleri commercially in the United States.
2022-2023: The Illumina-GRAIL combination became the subject of major antitrust and regulatory battles, leading to orders requiring divestiture. That controversy brought GRAIL unusually broad public attention for a diagnostics company.
2024: Illumina completed the spin-off of GRAIL, returning it to life as an independent public company listed on Nasdaq.

GRAIL’s history is therefore unusual: it moved rapidly from venture-backed moonshot, to strategic acquisition target, to the center of a landmark regulatory dispute, and then back to independent public-company status. That history still shapes the company’s operating priorities today.

15. What Are the Key Suppliers to GRAIL?

Suppliers matter strategically for GRAIL because its assay depends on specialized sequencing, laboratory consumables, and reliable sample logistics. Public filings have highlighted the importance of key third-party suppliers and the risk that some inputs may come from single or limited sources.

Sequencing instruments and consumables. Historically, Illumina has been the most obvious critical supplier because GRAIL’s testing workflow depends on next-generation sequencing instruments and related consumables. After the 2024 spin-off, what had previously been an intra-group relationship became a supplier relationship.
Laboratory reagents and consumables. Extraction kits, plastics, sample-prep inputs, and other specialized lab materials directly affect throughput, test quality, and failure rates.
Blood collection and sample-handling inputs. Collection tubes, kit components, and packaging matter because pre-analytical quality is critical in cell-free DNA testing.
Logistics and courier partners. Timely and reliable movement of blood samples from draw sites to the lab is operationally important.
Software and infrastructure vendors. While not the scientific core, data infrastructure, workflow systems, and secure computing environments are necessary for a scaled clinical-lab business.

Supplier structure matters because assay validation is not infinitely portable. Changing a major input or platform can require time, revalidation work, and operational disruption.

16. What Are the Key Brands Owned by GRAIL?

Brand architecture is simple at GRAIL.

Galleri. Galleri is the company’s principal product brand and the one that matters commercially. It is positioned as a multi-cancer early detection blood test intended to complement recommended cancer screening.
GRAIL. The corporate brand matters with physicians, investors, partners, and clinical stakeholders, but it is secondary to Galleri in day-to-day commercial branding.

Branding is not GRAIL’s main strategic lever in the way it would be for a consumer packaged-goods company. Clinical evidence, physician trust, and reimbursement are more important. Still, Galleri is an important brand because category creation in healthcare requires a high-trust product identity.

17. How Is GRAIL Using AI?

The clearest public AI use case at GRAIL is inside the product itself. Galleri uses machine-learning methods to analyze methylation patterns in cell-free DNA sequencing data and determine whether a cancer signal is present. If a signal is detected, the model also helps predict the cancer signal origin. This is a live operational use case, not a future concept.

Public disclosures also imply continued model refinement as GRAIL gathers more clinical and real-world data. In other words, AI at GRAIL is not mainly about generic productivity tools; it is central to assay performance, classification accuracy, and product differentiation.

18. How Does the Supply Chain of GRAIL Function?

GRAIL’s supply chain is best understood as a sample-to-result chain rather than a traditional factory-to-warehouse chain.

Procurement of specialized inputs. GRAIL sources sequencing consumables, blood collection materials, reagents, and lab equipment.
Kit and sample preparation. Ordering and collection workflows require the right kit components and sample-handling materials to be available where patients are drawn.
Sample transportation. Blood specimens must move reliably from collection sites to the laboratory with tight control over timing and handling.
Laboratory processing. Once received, samples move through accessioning, preparation, sequencing, and bioinformatics steps.
Result delivery. Outputs move digitally to clinicians and customer-support workflows rather than physically to a retail shelf.

Supply-chain reliability is strategically important because delays or disruptions affect turnaround time, customer satisfaction, laboratory utilization, and sometimes sample viability. For GRAIL, procurement, lab operations, and logistics are tightly interconnected.

19. What Is the Technology Strategy of GRAIL?

Technology is central to GRAIL’s competitiveness. The company is not trying to build sequencing hardware; instead, it is building a proprietary technology stack on top of sequencing infrastructure. That stack includes assay design, methylation analytics, bioinformatics pipelines, machine-learning classification, and laboratory software.

There are two sides to the technology strategy. First, technology is part of the customer offering: Galleri’s value depends on the quality of the underlying analytical and computational system. Second, technology is an internal enabler: automation, software workflow, data management, and lab systems all matter for cost per test and scalability.

A reasonable synthesis is that GRAIL’s technology strategy is aimed at widening three gaps at once: the clinical-performance gap versus simpler tests, the evidence gap versus newer entrants, and the cost-and-throughput gap that must narrow for the business model to scale.

20. What Is the R&D Strategy of GRAIL?

R&D is a major strategic pillar for GRAIL. The company is not just refining a mature product; it is still building the scientific and evidentiary foundation for a new screening category. That makes GRAIL’s R&D agenda broader than standard assay optimization.

Clinical validation. Studies such as the Circulating Cell-free Genome Atlas, PATHFINDER, and the NHS-Galleri trial are central to demonstrating performance and supporting real-world adoption.
Assay improvement. GRAIL continues to invest in improving sensitivity, operational robustness, and cost efficiency.
Algorithm and data science development. The classifier behind Galleri depends on continued improvement as more data are generated.
Health-economic and clinical utility evidence. For GRAIL, R&D extends beyond wet lab science into evidence that can support reimbursement and routine use.

This is one reason GRAIL’s expense base remains high relative to current revenue. The company is funding not only product development, but also the evidence architecture required to make multi-cancer early detection more widely accepted.

21. How Companies Like GRAIL Leverage Independent Consultants through Umbrex

GRAIL’s agenda spans category creation, reimbursement, clinical evidence, laboratory scaling, and post-spin operating-model work. Companies like GRAIL engage Umbrex when they need talent with the training of McKinsey, Bain, BCG, and other top consulting firms, but do not need a full consulting team with all the overhead. Umbrex has built a global community of more than 8,000 independent management consultants across more than 50 countries, with capabilities spanning Strategy, Operations, Organization, Marketing, Sales, Finance, Technology, ERP, and AI.

Channel segmentation and go-to-market prioritization across physicians, health systems, employers, and consumer-initiated access pathways.
Market access and reimbursement strategy, including evidence-to-coverage planning and payer value proposition development.
Sales-force design, account-coverage model redesign, and territory planning for an evidence-heavy diagnostic product.
Patient journey and access-friction reduction from order entry to blood draw, lab processing, result delivery, and follow-up support.
Laboratory operations improvement focused on turnaround time, throughput, quality systems, and cost per test.
Strategic sourcing and supply-risk management for sequencing consumables, lab reagents, and specimen logistics.
Post-spin operating-model design, including standalone-function optimization in procurement, finance, IT, and shared services.
Clinical evidence portfolio prioritization and program-management support across trials, publications, and health-economic initiatives.
International market assessment for selected geographies where public-health systems or large employers may support early adoption.
AI and data strategy projects tied to algorithm roadmap governance, commercial analytics, and data-infrastructure scaling.